drugset / Trial / NCT07000526
Inhaled Sedation in Critically Ill Patients
Phase 4
Recruiting
620 enrolled
Instituto de Investigación Hospital Universitario La Paz
Instituto de Salud Carlos III · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The proposal of this study is to compare inhaled sedation with isoflurane administered via the Sedaconda ACD-S system with intravenous sedation with propofol. Patients will be randomized 1:1 to receive either inhaled sedation with isoflurane administered via the Sedaconda ACD device (Sedana Medical, Uppsala, Sweden) or intravenous propofol. The primary endpoint is the number of ventilator-free days at 28 days after randomization.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2027-03
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isoflurane | Other / unclassified | 3 ml | Inhaled |
| Comparator | Propofol | Small molecule | 0.5 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 1 mg/kg | Intravenous |
Indications
No indication recorded.